Established in 2007, Restalyst is a trusted provider of innovative, reliable and clinically-proven diagnostic solutions to the medical and healthcare industry. We are a fully integrated company that generates the full product pipelines from scientific research to in-house developmental work of patented technology. Our key products include immunoassays for early diagnosis and sensitive detection of oncology and infectious diseases. Our R&D and production facilities are certified for compliance to EN ISO13485:2016.
Restalyst has successfully developed and launched three cancer tests for early detection of cancer for nose, stomach and liver cancer. We have also developed and launched two antibody assays for diagnosis of COVID-19 which have received Singapore HSA Provisional Authorization and CE mark in July/August this year.
We are actively engaging international partners to market and distribute these products globally beyond Asia Pacific into Europe, Middle East, Africa, and America. It is our goal to be a major in-vitro diagnostics manufacturer offering innovative & relevant diagnostic solutions at affordable prices to our clients all over the world.
To tap on our knowledge & experience, Restalyst also offers contract services in product development, manufacturing & commercialization.